doi:10.1038/s41430-023-01314-7 Witkowski M, Nemet I, Alamri H, et al
Unlike daily oral medications, where timing relative to meals or circadian rhythms can significantly alter absorption, a once-weekly injectable agent maintains a broadly consistent exposure profile regardless of the time of day it is administered
Moreover, Glutathione is not yet recommended by the FDA, which is a serious matter to consider
We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes
Data were extracted as follows: (1) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), fetal effects of maternal GLP-1 agonist or SGLT2 inhibitor exposure, (2) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), the transfer of GLP-1 agonist or SGLT2 inhibitor in maternal milk and the effect of exposure during lactation on the neonate